SCHEMBL3776218

SCHEMBL3776218

O=C(Nc1cccc(F)c1)c1cn2cc(-c3cn[nH]c3)ccc2n1

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.53
NR4A2 P43354 2/20 0.51
CYP2C9 P11712 1/20 0.51
USP30 Q70CQ3 1/20 0.49
MAP3K5 Q99683 1/20 0.48
NTRK1 P04629 2/20 0.47
ROCK2 O75116 3/20 0.46
DGAT1 O75907 1/20 0.46
CLK1 P49759 1/20 0.46
CLK2 P49760 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767210 0.87 CYP2C9 (0.65) EGLN1NR4A2CYP2C9USP30MAP3K5
SCHEMBL3778173 0.85 NR4A2 (0.53) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3774030 0.85 EGLN1 (0.54) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3719799 0.84 NR4A2 (0.53) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3779243 0.83 NR4A2 (0.55) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3765085 0.81 EGLN1 (0.50) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3369748 0.81 EGLN1 (0.71) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3779886 0.81 NR4A2 (0.78) EGLN1NR4A2CYP2C9
SCHEMBL3766957 0.81 NR4A2 (0.57) EGLN1NR4A2CYP2C9DGAT1
SCHEMBL3777768 0.81 EGLN1 (0.54) EGLN1NR4A2CYP2C9DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225240-B1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2014-01-22 EP claimed
US-8314109-B2 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-20 US claimed
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US claimed
US-8691990-B2 6-heterocyclic imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2014-04-08 US disclosed
EP-2225240-B1 Derivatives of 6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof SANOFI SA (FR) 2014-01-22 EP disclosed
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF PEYRONEL JEAN-FRANCOIS (FR) 2013-02-14 US disclosed
US-8314109-B2 6-heterocyclic-imidazo[1,2-α]pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-20 US disclosed
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041152-A1 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF XDH, REN, IDH2 EGLN1 1986/4885NR4A2 2105/4885CYP2C9 209/4885
US-20100317675-A1 6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF REN, IDH2, GLS EGLN1 1845/4885NR4A2 1987/4885CYP2C9 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.